Overcoming chemotherapy resistance
Our goal at Scandion Oncology is to develop drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is our mission.
Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy.
Although many cancer patients initially benefit from chemotherapy, a large proportion develop resistance against chemotherapy drugs. Few of these patients survive.Read more about us
CEO, Nils Brünner says
“Scandion Oncology is extremely proud to be listed on Spotlight Stock Market and had it first day of trading shares on Nov. 8, 2018. This was celebrated at Spotlight with a ceremonious event ringing the opening bell. Scandion Oncology looks forward to continue the hard work to fulfill the expectations of our shareholders. The first day of trading was a success and the share price raised more than 50%.”